ClinicalTrials.gg
RecruitingNCT07535307Updated Apr 24, 2026

Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes

A Phase 1 interventional study of NNC0487-0111 and Placebo in Diabetes Mellitus, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.

Planned enrollment
262nd of 494
80 · median 87
Started
2026
with 1 other
Phase 1
206 of 642
1 open now
Registered
641st of 642
by date

Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 262nd largest by planned enrollment of the 494 interventional ones that give a count, is one of 2 that started in 2026, is one of 206 in phase 1, and was the 641st registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 642 studies in Diabetes Mellitus by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of this clinical study is to find out how NNC0487-0111 affects, how the body uses insulin (a hormone that helps the body control blood sugar) and how well the pancreas works in people living with type 2 diabetes. There are 2 study treatments. Participants will get either NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age 18-75 years (both inclusive) at the time of signing the .
  • Diagnosed with type 2 diabetes more than or equal to (≥)180 days before screening.
  • Only stable daily dose(s) of metformin at effective or maximum tolerated dose, as judged by the investigator for at least 90 days before screening. If additional oral antidiabetic drug (OAD) is required, only stable dose(s) of sodium-glucose cotransporter-2 inhibitors (SGLT2i) is permitted, and this must also have been maintained for at least 90 days before screening.
  • at screening of 6.5-9.5% [48-80 millimole per mole (mmol/mol)] (both inclusive) if on metformin only, or 6.0-9.0% (42-75 mmol/mol) (both inclusive) if on metformin in combination with SGLT2i.

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using highly effective method.
  • Presence of type 1 diabetes.
  • Any body weight change (≥5% self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening.
  • Treatment with any medication for the indication of T2D or weight management other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Treatment with a GLP-1 receptor agonist.
  • Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) before screening or are expected to require treatment after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Presence or history of cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, , stroke, cardiac decompensation, clinically significant arrhythmias or clinically significant conduction disorders within 180 days before screening.
  • Renal impairment with estimated (eGFR) less than (\<) 60.0 milliliter per minute per meter square (ml/min/1.73 m\^2) at screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    NNC0487-0111 dose level 1

    Participants will be randomized to receive NNC0487-0111 dose level 1 subcutaneously once weekly.

    Drug: NNC0487-0111

  • Experimental
    NNC0487-0111 dose level 2

    Participants will be randomized to receive NNC0487-0111 dose level 2 subcutaneously once weekly.

    Drug: NNC0487-0111

  • Experimental
    NNC0487-0111 dose level 3

    Participants will be randomized to receive NNC0487-0111 dose level 3 subcutaneously once weekly.

    Drug: NNC0487-0111

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly.

    Drug: Placebo

Interventions

  • NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to the abdomen.

  • DrugPlacebo

    Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to the abdomen.

06

What researchers measure

Primary outcomes

  1. Change in M-value in Hyperinsulinaemic euglycaemic clamp (HEC)

    Measured as milligram per minute per kilogram (mg/min/kg)

    Time frame: Baseline to week 40

Secondary outcomes

  1. Change in M-value in HEC, normalised by lean body mass

    Measured as mg/min/kg

    Time frame: Baseline to week 40

  2. Change in first-phase incremental Insulin Secretion Rate (ISR0-8 min) in Hyperglycaemic clamp (HGC)

    Measured as picomole per minute per meter square (pmol/min/m\^2)

    Time frame: Baseline to week 40

  3. Change in second-phase ISR (ISR20-120 min) in HGC

    Measured as pmol/min/m\^2

    Time frame: Baseline to week 40

  4. Change in total ISR (ISR0-120 min) in HGC

    Measured as pmol/min/m\^2

    Time frame: Baseline to week 40

  5. Change in ISR at fixed glucose concentration (ISRg) in HGC

    Measured as pmol/min/m\^2

    Time frame: Baseline to week 40

  6. Change in total insulin response [total area under curve (AUC0-120) min] in HGC

    Measured as picomole per liter per minute (min\*pmol/L)

    Time frame: Baseline to week 40

  7. Change in clamp disposition index (cDI) calculated from HEC and HGC

    Measured as picomole per liter per meter square per minute square per kilogram (pmol\*L/m\^2/min\^2/kg)

    Time frame: Baseline to week 40

  8. Change in cDI calculated from HEC and HGC, based on lean body mass

    Measured as pmol\*L/m\^2/min\^2/kg

    Time frame: Baseline to week 40

  9. Change in β-cell glucose sensitivity (insulin secretion) from HGC

    Measured as picomole per minute per meter square per millimoles per liter \[pmol/min/m\^2/ (mmol/L)\]

    Time frame: Baseline to week 40

  10. Change in β-cell glucose sensitivity from mixed meal tolerance test (MMTT) (slope of dose-response for insulin secretion vs. plasma glucose)

    Measured as pmol/min/m\^2/ (mmol/L)

    Time frame: Baseline to week 40

  11. Change in glycated haemoglobin (HbA1c)

    Measured as percentage (%) of HbA1c

    Time frame: Baseline to week 40

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 19 months after the start.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 19 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 17, 2026
StartActual
Apr 10, 2026
Primary completionEst.
Nov 11, 2027
CompletionEst.
Dec 6, 2027
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07535307
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
Apr 10, 2026
Primary completion
Nov 11, 2027 (estimated)
Completion
Dec 6, 2027 (estimated)
Last update
Apr 24, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion